iBio, Inc.
IBIOiBio, Inc. in brief
iBio, Inc. is a listed company in the Biotechnology industry, based in Delaware, USA. Its market value was $59 M on 9 October 2026, which makes it the 20,697th largest listed company in the world and the 3,786th largest in the USA on this site. In the year to June 2026 it had sales of $0 M and a net loss of $33 M. Its largest product and service lines by sales in 2026 were Collaborative Revenues (100%). Its shares trade under the symbol IBIO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About iBio, Inc.
iBio, Inc is a Biotechnology company focused on contract development and manufacturing services as well as deploying them for the advancement of own pipeline of therapeutics, vaccines and products for research and bioprocessing applications. The company annual revenue is 2.3 million USD and total assets are 146.9 million USD as on 2021. The headquarters is in USA.
iBio, Inc. timeline
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed iBioPharma, Inc.Formerly InB:Biotechnologies, Inc..
- 2009
- ✎Renamed iBio, Inc.Formerly iBioPharma, Inc..
- 2021
- 💰Record revenue of $2 millionFY2021, the highest of the 8 years on record.
Events of iBio, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,306 (Jan 2022) · #5,809 (Dec 2022) · #5,458 (Jul 2023) · #4,685 (Jan 2024) · #1,962 (Mar 2026) · #3,602 (Aug 2026) · #3,767 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 591.6×
- Price / book
- 0.7×
- Free cash flow yield
- -40.2%
- Net margin
- -33040.0%
- Operating margin
- -35140.0%
- Return on equity
- -38.5%
- Liabilities / assets
- 13.5%
- Revenue growth
- -75.0%
- R&D / revenue
- 19640.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $0M | -75.0% | $-35M | $-33M | -33040.0% |
| Jun 2025 | $0M | +81.8% | $-19M | $-18M | -4595.0% |
| Jun 2024 | $0M | — | $-17M | $-25M | -11322.7% |
| Jun 2023 | — | — | $-29M | $-65M | — |
| Jun 2022 | $2M | -20.7% | $-30M | $-50M | -2675.5% |
| Jun 2021 | $2M | +44.5% | $-31M | $-23M | -979.3% |
| Jun 2020 | $2M | -18.8% | $-14M | $-16M | -1002.4% |
| Jun 2019 | $2M | — | $-16M | $-18M | -870.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2026 | $-23M | $1M | $-24M | $-0.32 | — |
| Jun 2025 | $-15M | $0M | $-15M | $-1.75 | — |
| Jun 2024 | $-19M | $0M | $-19M | $-6.50 | — |
| Jun 2023 | $-30M | $6M | $-36M | $-106.19 | — |
| Jun 2022 | $-37M | $7M | $-45M | $-5.78 | — |
| Jun 2021 | $-30M | $5M | $-35M | $-3.00 | — |
| Jun 2020 | $-13M | $1M | $-14M | $-0.61 | — |
| Jun 2019 | $-14M | $1M | $-15M | $-0.94 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (+980.0% on a year earlier), net income $-8M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 19, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- Oct 13, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 4, 2026DEF 14AProxy statement
- Aug 28, 202610-KAnnual report · period to Jun 2026
- Aug 28, 20268-KCurrent reportResults of operations
- Aug 4, 20268-KCurrent reportDirectors or officers changed · Other events
- Jul 17, 20268-KCurrent reportOther events
- Jul 1, 20268-KCurrent reportRegulation FD disclosure · Other events
- May 12, 202610-QQuarterly report · period to Mar 2026
Official filings of iBio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-35 M
- Net income
- $-33 M
For year ending June-2026 · source: SEC filing
Balance sheet
- Total assets
- $99 M
- Total liabilities
- $13 M
- Total equity
- $86 M
As of June-2026
Top 60 institutional investors in iBio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Silverarc Capital Management, LLC | 5,357,088 | +1,836,598 (+52.17%) | 8.33% | $6 M | Nov 12, 2026 |
| 2 | Affinity Asset Advisors, LLC | 4,130,427 | +122,546 (+3.06%) | 6.42% | $5 M | Nov 13, 2026 |
| 3 | Cormorant Asset Management, LP | 3,570,000 | 0 (0.00%) | 5.55% | $4 M | Nov 16, 2026 |
| 4 | Vestal Point Capital, LP | 2,600,000 | 0 (0.00%) | 4.04% | $3 M | Nov 16, 2026 |
| 5 | Woodline Partners LP | 2,238,450 | +461,903 (+26.00%) | 3.48% | $3 M | Nov 16, 2026 |
| 6 | Vanguard Capital Management LLC | 2,098,151 | 0 (0.00%) | 3.26% | $2 M | Nov 13, 2026 |
| 7 | Frazier Life Sciences Management, L.P. | 1,953,467 | 0 (0.00%) | 3.04% | $2 M | Nov 16, 2026 |
| 8 | Balyasny Asset Management L.P. | 1,592,008 | +421,115 (+35.97%) | 2.48% | $2 M | Nov 16, 2026 |
| 9 | Ensign Peak Advisors, Inc | 1,565,758 | -266,699 (-14.55%) | 2.43% | $2 M | Nov 12, 2026 |
| 10 | Bank Of America Corp /de/ | 1,488,537 | +367,045 (+32.73%) | 2.31% | $2 M | Nov 16, 2026 |
| 11 | Millennium Management LLC | 1,423,043 | -228,430 (-13.83%) | 2.21% | $2 M | Nov 16, 2026 |
| 12 | Ikarian Capital, LLC | 957,062 | 0 (0.00%) | 1.49% | $1 M | Nov 16, 2026 |
| 13 | Sio Capital Management, LLC | 904,268 | 0 (0.00%) | 1.41% | $1 M | Nov 16, 2026 |
| 14 | Atom Investors LP | 881,558 | +780,001 (+768.04%) | 1.37% | $1 M | Nov 16, 2026 |
| 15 | Marshall Wace, LLP | 766,195 | -137,937 (-15.26%) | 1.19% | $1 M | Nov 13, 2026 |
| 16 | Renaissance Technologies LLC | 688,400 | +485,553 (+239.37%) | 1.07% | $1 M | Nov 12, 2026 |
| 17 | Citadel Advisors LLC | 666,171 | -717,858 (-51.87%) | 1.04% | $1 M | Nov 16, 2026 |
| 18 | Geode Capital Management, LLC | 525,983 | +25,167 (+5.03%) | 0.82% | $1 M | Nov 6, 2026 |
| 19 | Walleye Capital LLC | 400,043 | -100,332 (-20.05%) | 0.62% | $0 M | Nov 13, 2026 |
| 20 | ADAR1 Capital Management, LLC | 375,531 | 0 (0.00%) | 0.58% | $0 M | Nov 16, 2026 |
| 21 | Sofinnova Investments, Inc. | 371,700 | New | 0.58% | $0 M | Nov 16, 2026 |
| 22 | BlackRock, Inc. | 291,450 | +49,434 (+20.43%) | 0.45% | $0 M | Nov 13, 2026 |
| 23 | Vanguard Fiduciary Trust Co | 286,875 | 0 (0.00%) | 0.45% | $0 M | Nov 13, 2026 |
| 24 | Boothbay Fund Management, LLC | 254,412 | 0 (0.00%) | 0.40% | $0 M | Nov 16, 2026 |
| 25 | Noesis Capital Mangement Corp | 249,000 | -156,000 (-38.52%) | 0.39% | $0 M | Oct 26, 2026 |
Show all 60: investors 26 to 60
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Two Sigma Investments, LP | 240,272 | -160,395 (-40.03%) | 0.37% | $0 M | Nov 16, 2026 |
| 27 | State Street Corp | 218,952 | +48,153 (+28.19%) | 0.34% | $0 M | Nov 12, 2026 |
| 28 | Goldman Sachs Group Inc | 200,308 | -147 (-0.07%) | 0.31% | $0 M | Nov 16, 2026 |
| 29 | Verdad Advisers, LP | 196,818 | -102,109 (-34.16%) | 0.31% | $0 M | Nov 16, 2026 |
| 30 | DAFNA Capital Management LLC | 170,053 | 0 (0.00%) | 0.26% | $0 M | Nov 16, 2026 |
| 31 | XTX Topco Ltd | 165,226 | +107,384 (+185.65%) | 0.26% | $0 M | Nov 16, 2026 |
| 32 | Morgan Stanley | 126,250 | +126,240 (+1262400.00%) | 0.20% | $0 M | Nov 13, 2026 |
| 33 | Squarepoint Ops LLC | 112,153 | -386,719 (-77.52%) | 0.17% | $0 M | Nov 9, 2026 |
| 34 | Northern Trust Corp | 111,319 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 35 | HRT Financial LP | 92,676 | New | 0.14% | $0 M | Nov 13, 2026 |
| 36 | Landscape Capital Management, L.L.C. | 88,796 | New | 0.14% | $0 M | Nov 10, 2026 |
| 37 | Vanguard Global Advisers, LLC | 30,356 | +24,896 (+455.97%) | 0.05% | $0 M | Nov 13, 2026 |
| 38 | UBS Group AG | 30,328 | +29,827 (+5953.49%) | 0.05% | $0 M | Nov 10, 2026 |
| 39 | R Squared Ltd | 24,153 | New | 0.04% | $0 M | Nov 6, 2026 |
| 40 | Readystate Asset Management LP | 21,694 | New | 0.03% | $0 M | Nov 16, 2026 |
| 41 | Spark Investment Management LLC | 17,600 | +4,100 (+30.37%) | 0.03% | $0 M | Nov 13, 2026 |
| 42 | StoneX Group Inc. | 16,087 | New | 0.03% | $0 M | Nov 3, 2026 |
| 43 | Bank of New York Mellon Corp | 10,636 | -1 (-0.01%) | 0.02% | $0 M | Nov 5, 2026 |
| 44 | Jpmorgan Chase & Co | 1,436 | -4,461 (-75.65%) | 0.00% | $0 M | Nov 12, 2026 |
| 45 | Tower Research Capital LLC (TRC) | 1,224 | New | 0.00% | $0 M | Nov 16, 2026 |
| 46 | Royal Bank Of Canada | 1,194 | New | 0.00% | $0 M | Nov 16, 2026 |
| 47 | Fortitude Family Office, LLC | 431 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 48 | Osaic Holdings, Inc. | 380 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 49 | FMR LLC | 220 | -213 (-49.19%) | 0.00% | $0 M | Nov 10, 2026 |
| 50 | Caitong International Asset Management Co., Ltd | 60 | +51 (+566.67%) | 0.00% | $0 M | Oct 29, 2026 |
| 51 | SBI Securities Co., Ltd. | 42 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 52 | SOA Wealth Advisors, LLC. | 13 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 53 | Citigroup Inc | 7 | New | 0.00% | $0 M | Nov 4, 2026 |
| 54 | Jones Financial Companies Lllp | 6 | New | 0.00% | $0 M | Nov 13, 2026 |
| 55 | Wells Fargo & Company/mn | 4 | -97 (-96.04%) | 0.00% | $0 M | Nov 16, 2026 |
| 56 | Activest Wealth Management | 4 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 57 | Harbour Investments, Inc. | 3 | New | 0.00% | $0 M | Nov 9, 2026 |
| 58 | Robinhood Markets, Inc. | 3 | — | 0.00% | $0 M | Nov 18, 2026 |
| 59 | Barclays PLC | 2 | -3,253 (-99.94%) | 0.00% | $0 M | Nov 6, 2026 |
| 60 | BNP Paribas Financial Markets | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
Mutual funds holding iBio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.47 M | $3 M | 2.3% | <0.01% | +118% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 582,071 | $1 M | 0.91% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 187,860 | $0 M | 0.29% | <0.01% | +51% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 103,831 | $0 M | 0.16% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 63,803 | $0 M | 0.10% | <0.01% | +42% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 51,345 | $0 M | 0.08% | <0.01% | +62% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 29,586 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 19,435 | $0 M | 0.03% | <0.01% | +60% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 20,661 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 6,970 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 654 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 500 | $0 M | <0.01% | <0.01% | −55% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at iBio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Marc BanjakChief Legal Officer | Buy | +12,500 | $1.640 | $21 K | 23,566 | Form 4 |
| filed | Marc BanjakChief Legal Officer | Buy | +1,434 | $1.760 | $3 K | 25,000 | Form 4 |
| filed | Felipe DuranChief Financial Officer | Buy | +24,835 | $2.020 | $50 K | 35,974 | Form 4 |
| filed | Martin BrennerSee Remarks, Director | Buy | +12,336 | $2.020 | $25 K | 30,652 | Form 4 |
| filed | William D. ClarkDirector | Buy | +1,838 | $2.720 | $5 K | 1,838 | Form 4 |
| filed | Parada Antonio Bernardino GuimaraesDirector | Buyindirect | +183,823 | $2.720 | $500 K | 183,823 | Form 4 |
| filed | Gary SenderDirector | Buy | +9,191 | $2.720 | $25 K | 9,191 | Form 4 |
| filed | David ArkowitzDirector | Buy | +18,382 | $2.720 | $50 K | 18,382 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: iBio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 1-for-25 reverse split ; 1-for-10 reverse split
Trading halts
- 2025-12-08 14:38 UTC, code LUDP, resumed 14:43 UTC
- 2025-04-07 14:59 UTC, code LUDP, resumed 15:04 UTC
- 2025-04-07 14:42 UTC, code LUDP, resumed 14:47 UTC
- 2025-04-07 14:29 UTC, code LUDP, resumed 14:39 UTC
- 2025-04-07 14:23 UTC, code LUDP, resumed 14:28 UTC
Fails to deliver
- : 68,584 shares at $0.92
- : 19,654 shares at $1.01
- : 12,211 shares at $1.40
- : 22,006 shares at $1.43
- : 21,321 shares at $1.47
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
iBio, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 4), weakest in profitability (0 of 3). Fiscal year 2026; market cap of Oct 9, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median591.6×Price to sales 591.6× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-40.2%Free cash flow is -40.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.32 vs -1.75Diluted EPS -0.32 in fiscal 2026 against -1.75 the year before (report's currency).
- ✗Net income higher than five years earlier-$33 M-$33 M in fiscal 2026 against -$23 M in 2021.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$33 MNet income -$33 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-65.7%-65.7% in fiscal 2026.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.86 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-702.8×Operating income -702.8 times interest in fiscal 2026.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- ✗Altman Z-score outside the distress zone-2.71Z-score -2.71 (distress zone) for fiscal 2026.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
iBio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2026to Jun 30, 2026 | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.1−75.0%100% | 0.4+77.8%100% | 0.2—100% | 0−100%— | 1.9r2.4−20.5%100% | 2.4+44.7%100% | 1.6−18.8%100% | 2.0+355%100% | 0.4+12.7%100% | 0.4—100% | |
| Cost of revenue | — | — | — | — | 0.2−85.2%11.5% | 1.5+108%61.7% | 0.7—42.9% | — | — | — | |
| Gross profit | — | — | — | — | 2.2+138%115% | 0.9−2.8%38.3% | 0.9—57.1% | — | — | — | |
| Research and development | 20+136%19643% | 8.3+60.3%2078% | 5.2−49.8%2304% | 10+5.1%— | 9.8r18−1.6%522% | 10.0+180%421% | 3.6r3.2−34.7%218% | 5.5+37.3%271% | 4.0−3.2%898% | 4.1—1045% | |
| General and administrative | 11−0.9%10595% | 11−8.4%2673% | 12−38.6%5188% | 19−12.6%— | 22r34−1.3%1155% | 22+93.8%929% | 11r12−7.8%694% | 12+15.4%611% | 11+1.3%2407% | 11—2678% | |
| Operating expenses | 35+85.5%35241% | 19+12.7%4751% | 17−42.5%7493% | 29−7.1%— | 32r52−1.4%1676% | 32+114%1350% | 15r16−16.1%912% | 18+21.4%882% | 15+0.0%3304% | 15—3723% | |
| Operating income | −35—−35141% | −19—−4651% | −17—−7393% | −29—— | −30r−50—−1576% | −31—−1312% | −14—−855% | −16—−782% | −14—−3204% | −14—−3623% | |
| Interest and finance income | 2.2+392%2150% | 0.4+20.4%109% | 0.4+70.4%161% | 0.2+20.3%— | 0.2r0.2+26.4%9.4% | 0.1+833%5.9% | 0.0−80.0%0.9% | 0.1+400%3.7% | 0.0−61.5%3.4% | 0.0—9.9% | |
| Interest expense and finance costs | 0.1−75.0%53.0% | 0.2+23.3%53.0% | 0.2+107%76.4% | 0.1−94.1%— | 1.4−42.5%74.9% | 2.5−0.5%104% | 2.5+29.8%151% | 1.9−0.8%94.2% | 1.9−0.7%431% | 1.9—490% | |
| Other non-operating income (expense) | 2.1+832%2097% | 0.2−81.1%56.3% | 1.2+3622%529% | 0.0−82.6%— | 0.2r−0.6−97.7%9.8% | 7.9—333% | −2.4—−149% | −1.8—−89.6% | −1.9—−424% | −1.9—−473% | |
| Income before tax | −33—−33044% | −18—−4594% | — | — | — | — | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Income from continuing operations | — | — | — | −29—— | −30—−1566% | — | — | — | — | — | |
| Income from discontinued operations | — | — | −9.5—−4206% | −36—— | −21—−1104% | — | — | — | — | — | |
| Net income including minority interests | −33—−33044% | −18—−4594% | −25—−11070% | −65—— | −50—−2670% | −23—−979% | −16—−1004% | −18—−872% | −16—−3628% | −16—−4096% | |
| Minority interests' share of net income | — | — | — | — | −0.0—−0.1% | −0.0—−0.3% | −0.0—−0.3% | −0.0—−0.2% | −0.0—−0.7% | −1.6—−408% | |
| Net income attributable to shareholders | −33—−33044% | −18—−4594% | −25—−11070% | −65—— | −50—−2670% | −23—−979% | −16—−1004% | −18—−872% | −16—−3627% | −15—−3688% | |
| Earnings per share, basic | -0.32—— | -1.75—— | -6.50—— | -106.19r-5.31—— | -5.78—— | -3.00r-0.12—— | -0.61—— | -0.94—— | -1.54—— | -1.64r-0.16—— | |
| Earnings per share, diluted | -0.32—— | -1.75—— | -6.50—— | -106.19r-5.31—— | -5.78—— | -3.00r-0.12—— | -0.61—— | -0.94—— | -1.54—— | -1.64r-0.16—— | |
| Shares, weighted average (basic) | 104+891%— | 10+174%— | 3.8+526%— | 0.6r12−93.0%— | 8.7+11.5%— | 7.8—— | — | — | — | — | |
| Shares, weighted average (diluted) | 104+891%— | 10+174%— | 3.8+526%— | 0.6r12−93.0%— | 8.7+11.5%— | 7.8r196−87.5%— | 63+232%— | 19+78.0%— | 11+19.3%— | 8.9r89—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 56+557%56.9% | 8.6−39.6%37.0% | 14+230%49.5% | 4.3−81.0%10.4% | 23−70.7%22.8% | 77+40.4%52.7% | 55+1147%58.5% | 4.4r4.40.0%14.5% | 4.4r16−72.3%10.3% | 16r8.1—44.2% | |
| Short-term investments | 32—31.9% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Receivables | — | 0—0.0% | 0—0.0% | 0−100%0.0% | 1.0+135%1.0% | 0.4+468%0.3% | 0.1−22.7%0.1% | 0.1+29.3%0.3% | 0.1−57.1%0.2% | 0.2—0.5% | |
| Inventory | — | — | 0—0.0% | 0−100%0.0% | 3.9+14344%3.9% | 0.0—0.0% | — | — | — | — | |
| Other current assets | 3.1+198%3.1% | 1.0+38.1%4.5% | 0.7+12.8%2.6% | 0.7−57.1%1.6% | 1.5−25.2%1.6% | 2.1+867%1.4% | 0.2−26.2%0.2% | 0.3+5.1%0.9% | 0.3−2.5%0.6% | 0.3—0.8% | |
| Current assets | 92+849%93.0% | 9.7−38.0%41.9% | 16−40.3%54.5% | 26−41.7%63.7% | 45−56.9%45.3% | 105+69.4%71.2% | 62+1184%65.6% | 4.8−70.5%15.7% | 16+90.0%37.8% | 8.6—23.8% | |
| Property, plant and equipment | 3.1−2.4%3.1% | 3.2−12.9%13.6% | 3.6−13.9%12.6% | 4.2+207%10.2% | 1.4r37−84.1%1.4% | 8.6+136%5.9% | 3.7−85.0%3.9% | 24−3.1%79.7% | 25−1.7%58.4% | 26—71.1% | |
| Right-of-use (leased) assets | 1.7−18.7%1.7% | 2.1−14.6%8.8% | 2.4−11.8%8.4% | 2.7−11.3%6.6% | 3.1r5.0—3.1% | 0—0.0% | — | — | — | — | |
| Other intangible assets | 1.8−73.3%1.8% | 6.8+27.6%29.5% | 5.4−0.4%18.7% | 5.4+11.1%13.1% | 4.9+410%4.9% | 1.0−16.8%0.6% | 1.1−16.7%1.2% | 1.4−15.2%4.5% | 1.6−11.1%3.8% | 1.8—5.1% | |
| Total assets | 99+327%100% | 23−19.3%100% | 29−30.3%100% | 41−58.5%100% | 99−32.4%100% | 147+56.0%100% | 94+208%100% | 31−29.0%100% | 43+19.6%100% | 36—100% | |
| Accounts payable | 4.4+102%4.5% | 2.2+511%9.4% | 0.4−80.6%1.2% | 1.8−56.6%4.5% | 4.3+89.2%4.3% | 2.3+28.1%1.5% | 1.8+75.7%1.9% | 1.0+26.7%3.3% | 0.8+5.5%1.8% | 0.7—2.1% | |
| Current liabilities | 12+92.4%11.9% | 6.1+59.0%26.3% | 3.8−82.6%13.4% | 22r22−27.4%53.7% | 30+358%30.6% | 6.6+26.9%4.5% | 5.2+51.4%5.6% | 3.5+69.9%11.3% | 2.0+1.1%4.7% | 2.0—5.6% | |
| Lease liabilities (non-current) | 1.7−24.9%1.7% | 2.2−18.2%9.5% | 2.7−14.0%9.4% | 3.1−11.1%7.6% | 3.5r5.5—3.5% | 0—0.0% | — | — | — | — | |
| Total liabilities | 13+61.3%13.5% | 8.3+12.1%35.8% | 7.4−71.3%25.8% | 26−28.1%62.7% | 36−6.5%36.1% | 38+2.2%26.1% | 38+33.6%39.9% | 28+4.5%92.0% | 27−0.6%62.5% | 27—75.2% | |
| Retained earnings | −365—−369% | −332—−1433% | −314—−1092% | −289—−701% | −224—−225% | −174—−118% | −150—−160% | −106—−346% | −88—−205% | −72—−200% | |
| Shareholders' equity | 86+476%86.5% | 15−30.2%64.2% | 21+38.6%74.2% | 15−75.8%37.3% | 63−41.5%63.9% | 109+91.8%73.9% | 57+2199%60.1% | 2.5−84.8%8.1% | 16+81.4%37.5% | 8.9—24.8% | |
| Minority interests | — | — | — | — | — | −0.0—−0.0% | −0.0—−0.0% | −0.0—−0.0% | −0.0−300%−0.0% | 0.0—0.0% | |
| Total equity | 86+476%86.5% | 15−30.2%64.2% | 21+38.6%74.2% | 15−75.8%37.3% | 63−41.5%63.9% | 109+91.8%73.9% | 57+2204%60.1% | 2.5−84.8%8.0% | 16+81.3%37.5% | 8.9—24.8% | |
| Total liabilities and equity | 99+327%100% | 23−19.3%100% | 29−30.3%100% | 41−58.5%100% | 99−32.4%100% | 147+56.0%100% | 94+208%100% | 31−29.0%100% | 43+19.6%100% | 36—100% | |
| Shares outstanding | 56+188%— | 19+124%— | 8.6+749%— | 1.0r20−88.4%— | 8.7+0.1%— | 8.7r218−93.8%— | 140+595%— | 20+25.6%— | 16+80.0%— | 8.9r89—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | 0.2—8.9% | — | — | |
| Share-based compensation | 1.4−10.3%1373% | 1.5−24.9%383% | 2.0−53.6%906% | 4.4+0.3%— | 4.4+176%232% | 1.6+309%66.9% | 0.4+61.0%23.7% | 0.2−68.7%11.9% | 0.8−23.8%173% | 1.0—256% | |
| Cash from operating activities | −23—−23218% | −15—−3826% | −19—−8246% | −30—— | −37—−1989% | −30—−1268% | −13—−815% | −14—−693% | −13—−3036% | −13—−3341% | |
| Capital expenditure | −0.6—−578% | −0.0—−4.0% | −0.2—−93.3% | −5.7—— | −7.3—−389% | −4.9—−208% | −1.1—−65.8% | −0.9—−45.6% | −0.9—−210% | −1.3—−336% | |
| Intangible assets bought | — | — | — | — | −4.3—−228% | −0.2—−10.2% | −0.1—−4.6% | −0.1—−3.5% | −0.1—−32.7% | −0.3—−68.5% | |
| Acquisitions, net of cash acquired | — | — | — | −0.7—— | — | — | — | — | — | — | |
| Cash from investing activities | −32−4413%−31999% | 0.7−18.1%186% | 0.9−87.1%403% | 7.0—— | −5.1—−272% | −26—−1117% | −1.2—−70.5% | −1.0—−49.1% | −1.1—−243% | −1.6—−404% | |
| Shares issued | 3.5−0.3%3529% | 3.5−86.1%885% | 26+122%11344% | 11—— | — | — | — | — | — | 0—0.0% | |
| Cash from financing activities | 103+1054%103048% | 8.9−63.5%2232% | 24+964%10886% | 2.3—— | −6.1−108%−325% | 79+20.9%3325% | 65+1788%3980% | 3.5−84.6%171% | 22—5046% | −0.2—−43.1% | |
| Exchange-rate effect on cash | — | — | — | — | — | −0.0—−0.0% | −0.0—−0.1% | −0.0—−0.0% | −0.0—−0.2% | 0—0.0% | |
| Change in cash | 48—47831% | −5.6−182%−1408% | 6.8—3043% | −21—— | −49−319%−2587% | 22−56.0%940% | 51—3095% | −12−247%−571% | 7.8—1767% | −15—−3788% | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q1 FY2027to Sep 30, 2026 | Q4 FY2026to Jun 30, 2026 | Q3 FY2026to Mar 31, 2026 | Q2 FY2026to Dec 31, 2025 | Q1 FY2026to Sep 30, 2025 | Q4 FY2025to Jun 30, 2025 | Q3 FY2025to Mar 31, 2025 | Q2 FY2025to Dec 31, 2024 | Q1 FY2025to Sep 30, 2024 | Q4 FY2024to Jun 30, 2024 | Q3 FY2024to Mar 31, 2024 | Q2 FY2024to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 1.1+115%100% | 1.1+975%100% | 0*−100%— | 0*—— | 0−100%— | 0.1—100% | 0.2*+14.3%100% | 0—— | 0.2—100% | 0—— | 0.2*—100% | 0*—— | 0*—— | |
| Research and development | 23+115%2116% | 6.7+87.3%619% | 8.6*+165%— | 3.3+70.7%— | 4.3+128%— | 3.6+172%3550% | 3.2*+183%1612% | 1.9+111%— | 1.9+22.3%939% | 1.3—— | 1.1*—651% | 0.9—— | 1.5—— | |
| General and administrative | — | 2.8+10.5%257% | — | 5.1+71.9%— | 5.2+88.4%— | 2.5−10.7%2501% | 2.2*−11.0%1087% | 3.0+9.2%— | 2.7−7.4%1371% | 2.8—— | 2.4*—1397% | 2.7—— | 3.0—— | |
| Operating expenses | 39+84.3%3591% | 9.4+55.6%876% | 11*+111%— | 8.4+71.4%— | 9.4+104%— | 6.1+47.4%6051% | 5.4*+50.6%2699% | 4.9+34.6%— | 4.6+2.7%2310% | 4.1—— | 3.6*—2048% | 3.6—— | 4.5—— | |
| Operating income | −38—−3491% | −8.3—−776% | −11*—— | −8.4—— | −9.4—— | −6.0—−5951% | −5.2*—−2599% | −4.9—— | −4.4—−2210% | −4.1—— | −3.4*—−1948% | −3.6—— | −4.5—— | |
| Interest and finance income | 2.7+406%248% | 0.8+197%73.2% | 0.7*+828%— | 0.7+813%— | 0.5+340%— | 0.3r0.3+52.3%265% | 0.1*−64.6%39.5% | 0.1+67.4%— | 0.1+167%56.0% | 0.2—— | 0.2*—127% | 0.0—— | 0.0—— | |
| Interest expense and finance costs | — | — | — | 0.0−59.3%— | 0.0−28.1%— | 0.0r0.0−40.4%34.0% | 0.0*−26.7%22.0% | 0.1+3.8%— | 0.1+67.6%28.5% | 0.1—— | 0.1*—34.3% | 0.1—— | 0.0—— | |
| Other non-operating income (expense) | 2.7+683%247% | 0.8+241%73.2% | 0.8*+2126%— | 0.6+3428%— | 0.5+722%— | 0.2+97.4%231% | 0.0*−78.5%17.5% | 0.0−98.2%— | 0.1+588%27.5% | 0.1—— | 0.2*—93.1% | 1.0—— | 0.0—— | |
| Income before tax | — | −7.6—−702% | — | — | — | −5.7—−5720% | — | — | — | — | — | — | — | |
| Income tax | 0—0.0% | 0—0.0% | 0*—— | 0—— | 0—— | 0—0.0% | 0*—0.0% | 0—— | 0—0.0% | 0—— | 0*—0.0% | 0—— | 0—— | |
| Income from continuing operations | — | — | — | — | — | — | — | — | — | — | — | −2.6—— | −4.5—— | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | — | — | −4.5*—−2590% | −0.5—— | −3.7—— | |
| Net income including minority interests | −35—−3244% | −7.6—−702% | −11*—— | −7.7*—— | −9.0*—— | −5.7—−5720% | −5.2*—−2582% | −4.9*—— | −4.4*—−2182% | −4.0—— | −7.8*—−4445% | −3.2—— | −8.2—— | |
| Net income attributable to shareholders | −35—−3244% | −7.6—−702% | −11*—— | −7.7—— | −9.0—— | −5.7—−5720% | −5.2*—−2582% | −4.9—— | −4.4—−2182% | −4.0—— | −7.8*—−4445% | −3.2—— | −8.2—— | |
| Earnings per share, basic | — | -0.05—— | — | -0.06—— | -0.09—— | -0.11—— | — | -0.49—— | -0.48—— | -0.46—— | — | -0.85—— | -4.42—— | |
| Earnings per share, diluted | — | -0.05—— | — | -0.06—— | -0.09—— | -0.11—— | — | -0.49—— | -0.48—— | -0.46—— | — | -0.85—— | -4.42—— | |
| Shares, weighted average (basic) | 152+186%— | 152+186%— | — | 120+1113%— | 99+986%— | 53+514%— | — | 9.9+166%— | 9.1+392%— | 8.6—— | — | 3.7—— | 1.9—— | |
| Shares, weighted average (diluted) | 152+186%— | 152+186%— | — | 120+1113%— | 99+986%— | 53+514%— | — | 9.9+166%— | 9.1+392%— | 8.6—— | — | 3.7—— | 1.9—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 45—51.3% | 45+61.6%51.3% | 56+557%56.9% | 48+860%55.5% | 29+309%44.5% | 28+155%43.8% | 8.6−39.6%37.0% | 5.0−6.5%26.0% | 7.0+152%32.3% | 11—45.0% | 14—49.5% | 5.3—10.6% | 2.8—8.2% | |
| Short-term investments | 31—35.2% | 31+45.4%35.2% | 32—31.9% | 27—31.7% | 24—37.3% | 21—33.5% | 0—0.0% | — | — | — | 0—0.0% | — | — | |
| Receivables | 0.1—0.1% | 0.1+92.3%0.1% | — | — | — | 0.1—0.1% | 0—0.0% | — | — | — | 0—0.0% | — | — | |
| Inventory | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | |
| Other current assets | 3.3—3.8% | 3.3+193%3.8% | 3.1+198%3.1% | 2.5+123%2.9% | 0.7−46.7%1.0% | 1.1+70.9%1.8% | 1.0+38.1%4.5% | 1.1+27.7%5.8% | 1.3+40.6%5.8% | 0.7—2.7% | 0.7—2.6% | 0.9—1.7% | 0.9—2.6% | |
| Current assets | 81—91.6% | 81+60.0%91.6% | 92+849%93.0% | 77+1175%90.0% | 53+544%82.9% | 51+334%79.1% | 9.7−38.0%41.9% | 6.1−83.2%31.7% | 8.3−57.9%38.2% | 12—47.7% | 16—54.5% | 36—72.1% | 20—57.9% | |
| Property, plant and equipment | 3.0—3.4% | 3.0−5.9%3.4% | 3.1−2.4%3.1% | 3.3+0.8%3.9% | 3.4+1.7%5.4% | 3.2−8.6%5.0% | 3.2−12.9%13.6% | 3.3−11.9%17.2% | 3.4−12.8%15.6% | 3.5—14.3% | 3.6—12.6% | 3.7—7.4% | 3.9—11.4% | |
| Right-of-use (leased) assets | 1.6—1.8% | 1.6−6.1%1.8% | 1.7−18.7%1.7% | 1.8−17.6%2.1% | 1.9−16.4%2.9% | 1.7r2.0−18.7%2.6% | 2.1−14.6%8.8% | 2.1−13.3%11.2% | 2.2−13.1%10.3% | 2.1r2.3—8.4% | 2.4—8.4% | 2.5—4.9% | 2.6—7.5% | |
| Other intangible assets | 2.6—2.9% | 2.6−62.4%2.9% | 1.8−73.3%1.8% | 1.8−70.0%2.1% | 4.3−29.0%6.7% | 6.8+27.6%10.7% | 6.8+27.6%29.5% | 6.1+13.6%31.9% | 6.1+13.6%28.2% | 5.4—21.9% | 5.4—18.7% | 5.4—10.7% | 5.4—15.8% | |
| Total assets | 89—100% | 89+38.2%100% | 99+327%100% | 86+349%100% | 64+197%100% | 64+162%100% | 23−19.3%100% | 19−61.9%100% | 22−36.2%100% | 25—100% | 29—100% | 50—100% | 34—100% | |
| Accounts payable | 4.4—5.0% | 4.4+56.2%5.0% | 4.4+102%4.5% | 3.0+105%3.5% | 2.7+332%4.1% | 2.8+230%4.4% | 2.2+511%9.4% | 1.5+20.3%7.7% | 0.6−67.0%2.8% | 0.9—3.5% | 0.4—1.2% | 1.2—2.4% | 1.9—5.5% | |
| Current liabilities | 8.6—9.7% | 8.6+41.8%9.7% | 12+92.4%11.9% | 6.5+20.5%7.6% | 5.9+25.3%9.2% | 6.0+74.3%9.4% | 6.1+59.0%26.3% | 5.4−74.8%28.3% | 4.7−78.2%21.7% | 3.5—14.1% | 3.8—13.4% | 21—42.7% | 22—63.4% | |
| Lease liabilities (non-current) | 1.5—1.7% | 1.5−8.8%1.7% | 1.7−24.9%1.7% | 1.8−22.9%2.1% | 1.9−21.1%3.0% | 1.7r2.1−24.9%2.6% | 2.2−18.2%9.5% | 2.3−17.0%12.2% | 2.5−15.9%11.3% | 2.2r2.6—9.0% | 2.7—9.4% | 2.8—5.6% | 2.9—8.6% | |
| Total liabilities | 10—11.4% | 10+24.2%11.4% | 13+61.3%13.5% | 8.3+7.4%9.7% | 7.8+0.4%12.2% | 8.1+20.0%12.7% | 8.3+12.1%35.8% | 7.7−69.5%40.4% | 7.8−68.6%36.0% | 6.8—27.6% | 7.4—25.8% | 25—50.4% | 25—73.0% | |
| Retained earnings | −373—−421% | −373—−421% | −365—−369% | −355—−413% | −347—−539% | −338—−527% | −332—−1433% | −327—−1712% | −322—−1485% | −318—−1296% | −314—−1092% | −306—−610% | −303—−890% | |
| Shareholders' equity | 79—88.6% | 79+40.2%88.6% | 86+476%86.5% | 78+581%90.3% | 57+307%87.8% | 56+216%87.3% | 15−30.2%64.2% | 11−54.2%59.6% | 14+51.1%64.0% | 18—72.4% | 21—74.2% | 25—49.6% | 9.2—27.0% | |
| Total equity | 79—88.6% | 79+40.2%88.6% | 86+476%86.5% | 78+581%90.3% | 57+307%87.8% | 56+216%87.3% | 15−30.2%64.2% | 11−54.2%59.6% | 14+51.1%64.0% | 18—72.4% | 21—74.2% | 25—49.6% | 9.2—27.0% | |
| Total liabilities and equity | 89—100% | 89+38.2%100% | 99+327%100% | 86+349%100% | 64+197%100% | 64+162%100% | 23−19.3%100% | 19−61.9%100% | 22−36.2%100% | 25—100% | 29—100% | 50—100% | 34—100% | |
| Shares outstanding | 64—— | 64+217%— | 56+188%— | 35+243%— | 30+228%— | 20+134%— | 19+124%— | 10+18.2%— | 9.2+183%— | 8.6—— | 8.6—— | 8.5—— | 3.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 1.5+3.3%138% | 0.4+34.7%40.5% | 0.4*+55.6%— | 0.4+1.9%— | 0.3−46.7%— | 0.3−22.2%323% | 0.3*−25.0%135% | 0.4−18.5%— | 0.5+4.6%238% | 0.4—— | 0.4*—206% | 0.5—— | 0.5—— | |
| Cash from operating activities | −27—−2506% | −9.4—−873% | −6.2*—— | −6.1*—— | −5.2*—— | −5.7—−5665% | −4.6*—−2308% | −3.1*—— | −3.9*—−1935% | −3.7—— | −4.9*—−2774% | −3.7*—— | −4.7*—— | |
| Capital expenditure | −0.6—−60.3% | −0.1—−9.5% | −0.0*—— | −0.0*—— | −0.5*—— | −0.0—−32.0% | −0.0*—−0.5% | −0.0*—— | −0.0*—−0.5% | 0—— | −0.2*—−120% | 0*—— | — | |
| Intangible assets bought | — | −0.8—−69.8% | — | — | — | 0—0.0% | — | — | — | — | — | — | — | |
| Cash from investing activities | −11—−1020% | −0.5—−42.2% | −4.4*−9904%— | −3.1*—— | −3.0*—— | −21−3114%−21493% | 0.0*—22.5% | −0.0*−101%— | −0.0*—−1.0% | 0.7—— | −0.1*—−82.3% | 1.0*—— | 0*—— | |
| Shares issued | — | — | 0*−100%— | 3.3*+194%— | 0*—— | 0.2+5375%219% | 2.4*−83.2%1205% | 1.1*−73.6%— | 0*−100%0.0% | 0.0—— | 14*—8182% | 4.3*—— | 4.1*—— | |
| Cash from financing activities | 55−1.0%5137% | −1.1−102%−104% | 19*+137%— | 28*+2549%— | 8.8*—— | 47—46705% | 8.2*−37.0%4090% | 1.1*−78.8%— | −0.2*−104%−76.0% | −0.2—— | 13*—7424% | 5.0*—— | 4.0*—— | |
| Change in cash | 17+1.4%1612% | −11−156%−1020% | 8.8*+143%— | 19*—— | 0.6*—— | 20—19547% | 3.6*−54.8%1805% | −2.1*−187%— | −4.0*—−2011% | −3.2—— | 8.0*—4568% | 2.4*—— | −0.7*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q/A | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What iBio, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Collaborative Revenues$0 M100%-75%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
Executive pay at iBio, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Dr. Martin B. Brenner | $2.1 M | $2.3 M | $1.0 M | $14 |
| 2025Chief executive | $1.5 M | $622 K | $741 K | $6 |
| 2024Chief executive | $1.3 M | $1.2 M | $762 K | $17 |
Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026
Events at iBio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 3 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2026 | $26 M | Private placement after listing | $10 to $50 million | 7 | options | SEC |
| Apr 2025 | $11 M | Private placement after listing | $10 to $50 million | 5 | options | SEC |
| Mar 2024 | $15 M | Private placement after listing | $10 to $50 million | 8 | equity, options | SEC |
| Jan 2016 | $2 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| Oct 2010 | $7 M | No. 2 | $2 to $10 million | 52 | equity, options | SEC |
| Sep 2009 | $3 M | No. 1 | $2 to $10 million | 26 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by iBio, Inc.#
$90 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues, medical/disease research/clinical labs and budget/appropriations.
- Health Issues3 reports
- Medical/Disease Research/Clinical Labs3 reports
- Budget/Appropriations3 reports
Lobbying firms hired in 2022
The Petrizzo Group, Inc. $90 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $90 K | — | 3 |
| 2021 | $120 K | — | 6 |
| 2020 | $110 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “iBio, Inc.” and “IBIO, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How iBio, Inc. compares in Biotechnology
- Market cap$59 M · higher than 29% of 726
- Revenue$0 M · higher than 16% of 647
- Revenue growth-75.0% · higher than 8% of 438
- Price / sales591.6× · lower than 1% of 339
- Price / book0.7× · lower than 85% of 534
- FCF yield-40.2% · higher than 28% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| iBio, Inc.🇺🇸 | $59 M | — | — | -75.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 9, 2026
- Annual results:
- For year ending June-2026
- Balance sheet:
- As of June-2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at iBio, Inc.? Verify and update this profile — free
Show iBio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.